Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity).

Richards S, Amaravadi L, Pillutla R, Birnboeck H, Torri A, Cowan KJ, Papadimitriou A, Garofolo F, Satterwhite C, Piccoli S, Wu B, Krinos-Fiorotti C, Allinson J, Berisha F, Cocea L, Croft S, Fraser S, Galliccia F, Gorovits B, Gupta S, Gupta V, Haidar S, Hottenstein C, Ishii-Watabe A, Jani D, Kadavil J, Kamerud J, Kramer D, Litwin V, Lima Santos GM, Nelson R, Ni Y, Pedras-Vasconcelos J, Qiu Y, Rhyne P, Safavi A, Saito Y, Savoie N, Scheibner K, Schick E, Siguenza PY, Smeraglia J, Staack RF, Subramanyam M, Sumner G, Thway T, Uhlinger D, Ullmann M, Vitaliti A, Welink J, Whiting CC, Xue L, Zeng R.

Bioanalysis. 2016 Dec;8(23):2475-2496.

2.

Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging.

Whiting CC, Siebert J, Newman AM, Du HW, Alizadeh AA, Goronzy J, Weyand CM, Krishnan E, Fathman CG, Maecker HT.

PLoS One. 2015 Jul 21;10(7):e0133627. doi: 10.1371/journal.pone.0133627. eCollection 2015.

3.

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.

Nair N, Mei HE, Chen SY, Hale M, Nolan GP, Maecker HT, Genovese M, Fathman CG, Whiting CC.

Arthritis Res Ther. 2015 May 18;17:127. doi: 10.1186/s13075-015-0644-z. Review.

4.

Inflammation and hyperglycemia mediate Deaf1 splicing in the pancreatic lymph nodes via distinct pathways during type 1 diabetes.

Yip L, Fuhlbrigge R, Taylor C, Creusot RJ, Nishikawa-Matsumura T, Whiting CC, Schartner JM, Akter R, von Herrath M, Fathman CG.

Diabetes. 2015 Feb;64(2):604-17. doi: 10.2337/db14-0803. Epub 2014 Sep 3.

5.

Diminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes.

Yip L, Taylor C, Whiting CC, Fathman CG.

Diabetes. 2013 Dec;62(12):4208-19. doi: 10.2337/db13-0614.

6.

GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness.

Whiting CC, Su LL, Lin JT, Fathman CG.

FEBS J. 2011 Jan;278(1):47-58. doi: 10.1111/j.1742-4658.2010.07922.x. Epub 2010 Nov 16. Review.

7.

Endogenous galectin-1 enforces class I-restricted TCR functional fate decisions in thymocytes.

Liu SD, Whiting CC, Tomassian T, Pang M, Bissel SJ, Baum LG, Mossine VV, Poirier F, Huflejt ME, Miceli MC.

Blood. 2008 Jul 1;112(1):120-30. doi: 10.1182/blood-2007-09-114181. Epub 2008 Mar 6.

8.

Dosing and timing effects of anti-CD40L therapy: predictions from a mathematical model of type 1 diabetes.

Gadkar KG, Shoda LK, Kreuwel HT, Ramanujan S, Zheng Y, Whiting CC, Young DL.

Ann N Y Acad Sci. 2007 Apr;1103:63-8. Epub 2007 Mar 21.

PMID:
17376835
9.

The virtual NOD mouse: applying predictive biosimulation to research in type 1 diabetes.

Zheng Y, Kreuwel HT, Young DL, Shoda LK, Ramanujan S, Gadkar KG, Atkinson MA, Whiting CC.

Ann N Y Acad Sci. 2007 Apr;1103:45-62. Epub 2007 Mar 21.

PMID:
17376834
10.

Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.

Young DL, Ramanujan S, Kreuwel HT, Whiting CC, Gadkar KG, Shoda LK.

Ann N Y Acad Sci. 2006 Oct;1079:369-73.

PMID:
17130581
11.

A comprehensive review of interventions in the NOD mouse and implications for translation.

Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT.

Immunity. 2005 Aug;23(2):115-26. Review.

12.

School performance of children who have experienced maltreatment.

Whiting CC.

Phys Occup Ther Pediatr. 2001;21(2-3):81-9. Review.

PMID:
12029857

Supplemental Content

Loading ...
Support Center